Mount Vernon Cancer Centre East & North Herts NHS Trust Trials

Mount Vernon Cancer Centre East & North Herts NHS Trust	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Maio, Michele

Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study

Recruiting

214

Europe

L19IL2 + L19TNF, Surgery

Philogen S.p.A.

Malignant Melanoma

10/24

12/25

KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting

407

Europe, US, RoW

IO102-IO103, Pembrolizumab

IO Biotech, Syneos Health, Merck Sharp & Dohme LLC

Metastatic Melanoma, Unresectable Melanoma

07/25

09/27

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy

Active, not recruiting

2/3

758

Europe, Canada, Japan, US, RoW

Cobolimab, Dostarlimab, Docetaxel

GlaxoSmithKline

Lung Cancer, Non-Small Cell

10/24

10/25

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

380

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Suspended

220

Europe, US, RoW

Botensilimab, AGEN1181, Balstilimab, AGEN2034

Agenus Inc.

Advanced Melanoma

05/28

SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated

205

Europe, US, RoW

ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda

Seagen Inc., Merck Sharp & Dohme LLC

Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma

11/23

NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Recruiting

185

Europe, Canada, US, RoW

Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608

GlaxoSmithKline, iTeos Belgium SA

Neoplasms

07/25

NCT02076646: A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Active, not recruiting

1/2

Europe

L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC, DETICENE®

Philogen S.p.A.

Metastatic Melanoma Stage IV

05/16

06/22

NCT05586516: A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Recruiting

1/2

Europe

IOA-289, gemcitabine, nab-paclitaxel, Abraxane

iOnctura

Metastatic Pancreatic Cancer

12/24

02/25

OMNIA-1, NCT05578872: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma ().

Recruiting

1/2

130

Europe, US

ANV419, Pembrolizumab, Ipilimumab

Anaveon AG

Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma

09/24

12/24

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer

08/25

07/26

KROCUS, NCT05756153: A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting

1/2

Europe

GFH925, Cetuximab

Zhejiang Genfleet Therapeutics Co., Ltd.

Advance Non-small Cell Lung Cancer

03/25

08/25

NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn

Europe, RoW

Encorafenib + Binimetinib, Braftovi + Mektovi

Pierre Fabre Medicament

BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment

05/23

DIONE-01, NCT04328844: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Active, not recruiting

210

Europe

IOA-244, Avelumab Injection, Pemetrexed, Cisplatin, Ruxolitinib

iOnctura

Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma

09/23

04/24

NCT04282083: Protocol ITANET - Registry

Recruiting

N/A

3600

Europe

Italian Association Neuroendocrine Tumors

Gastro-entero Pancreatic Neuroendocrine Tumors

07/27

07/32

Dynovisz, Annaelle

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

380

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

DiGuardo, Lorenza

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

380

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

Rossi, Ernesto

DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting

2/3

380

Europe, Canada, US, RoW

IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome

IDEAYA Biosciences

Metastatic Uveal Melanoma

01/27

01/28

NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting

Europe, Canada, US, RoW

Darovasertib, IDE196, LXS196

IDEAYA Biosciences

Uveal Melanoma

01/26

01/29



	Diseases Companies Products Productz Mechanisms of Action Sites